Septerna (SEPN) News Today

Septerna, Inc. (NASDAQ: SEPN) shares have climbed on the back of clinical trial milestones and supportive analyst actions. Below is a summary of recent investor-relevant developments:

• Positive Sentiment: Septerna began dosing the first participants in its Phase 1 clinical trial of SEP-631, an oral MRGPRX2 negative allosteric modulator for mast cell-driven diseases. GlobeNewswire
• Positive Sentiment: H.C. Wainwright reaffirmed its Buy rating on SEPN with a $26 price target, suggesting over 100% upside from current levels. Benzinga
• Positive Sentiment: Analyst Ram Selvaraju at H.C. Wainwright reiterated a Buy rating, citing advancements in clinical trials and strategic focus. Tipranks
• Positive Sentiment: H.C. Wainwright lifted its Q3 2025 EPS estimates for SEPN, reflecting improved near-term profitability expectations. MarketBeat
• Neutral Sentiment: Media outlets including Taiwan News and MSN reported on the Phase 1 dosing, highlighting broad coverage of Septerna’s trial progress. Taiwan News MSN
• Negative Sentiment: H.C. Wainwright cut its FY 2025 EPS forecast for SEPN, signaling downward revisions to full-year earnings expectations. MarketBeat
• Negative Sentiment: An H.C. Wainwright note issued a cautious outlook for Septerna’s earnings trajectory, flagging potential headwinds ahead. American Banking News